HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT
Author(s): ,
Donna Reece
Affiliations:
Princess Margaret Cancer Centre,Toronto,Canada
,
Nizar J. Bahlis
Affiliations:
University of Calgary,Calgary,Canada
,
Christy Samaras
Affiliations:
Cleveland Clinic,Cleveland,United States
,
Michael Sebag
Affiliations:
McGill University Health Centre,Montreal,Canada
,
Jesus Berdeja
Affiliations:
Sarah Cannon Research Institute,Nashville,United States
,
Siddhartha Ganguly
Affiliations:
The University of Kansas Cancer Center,Fairway,United States
,
Jeffrey Matous
Affiliations:
Colorado Blood Cancer Institute,Denver,United States
,
Kevin Song
Affiliations:
Vancouver General Hospital,Vancouver,Canada
,
Christopher S. Seet
Affiliations:
University of California, Los Angeles Medical Center,Los Angeles,United States
,
Giampaolo Talamo
Affiliations:
Penn State Hershey Cancer Institute,Hershey,United States
,
Mirelis Acosta-Rivera
Affiliations:
Fundación de Investigación,San Juan,Puerto Rico
,
Michael Bar
Affiliations:
Stamford Hospital,Stamford,United States
,
Donald Quick
Affiliations:
Joe Arrington Cancer Research and Treatment Center,Lubbock,United States
,
Bertrand Anz
Affiliations:
Tennessee Oncology,Chattanooga,United States
,
Gustavo Fonseca
Affiliations:
Florida Cancer Specialists,St Petersburg,United States
,
Amit Agarwal
Affiliations:
Celgene Corporation,Summit,United States
,
Weiyuan Chung
Affiliations:
Celgene Corporation,Summit,United States
,
Faiza Zafar
Affiliations:
Celgene Corporation,Summit,United States
David S. Siegel
Affiliations:
John Theurer Cancer Center, Hackensack University Medical Center,Hackensack,United States
EHA Library. Reece D. Jun 14, 2019; 266430; PF631
Donna Reece
Donna Reece
Contributions
Abstract

Abstract: PF631

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background
Treatment of relapsed refractory multiple myeloma (RRMM) is complex and requires evaluation of disease and patient factors to maximize efficacy and minimize toxicity. As survival has improved with therapeutic advances, maintaining quality of life has become an important aspect of multiple myeloma treatment. Results from cohort B of the ongoing phase 2 MM-014 trial (NCT01946477) have demonstrated that pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) is safe and effective in patients with RRMM after first- or second-line lenalidomide (LEN)-based treatment.

Aims
To evaluate the impact of POM+ LoDEX + DARA on health-related quality of life (HRQoL) in patients with RRMM who received this regimen after first- or second-line LEN.

Methods
Patients with RRMM and 1 to 2 prior lines of treatment, LEN-based treatment as their most recent regimen, and progressive disease during or after their last treatment line were eligible for inclusion in cohort B. In 28-day cycles, patients received POM 4 mg/day on days 1-21 + LoDEX 40 mg/day (20 mg/day if aged > 75 years) on days 1, 8, 15, and 22, and DARA 16 mg/kg IV on DEX dosing days of cycles 1 and 2, then on days 1 and 15 of cycles 3-6, and then on day 1 of cycle 7 and beyond. Thromboprophylaxis was mandatory. The primary endpoint was overall response rate. HRQoL, an exploratory endpoint for cohort B, was assessed via EQ-5D.

Results
As of 15 October 2018, 108 patients were evaluable for HRQoL. Baseline characteristics were similar to those of the ITT population (N = 112). EQ-5D completion rates for each cycle (1-6) were ≥ 88%. Through 6 treatment cycles, mean change from baseline in the EQ-5D index and VAS health score was stable. At cycle 6, minimum clinically important improvement in the EQ-5D index (≥ 0.1) and VAS health score (≥ 6) was achieved by 28.8% and 39.0% of patients, respectively. EQ-5D index values were stable; however, a trend toward improvement was observed in usual activities, pain/discomfort, and anxiety/depression (Figure).

Conclusion
In patients with RRMM who received POM + LoDEX + DARA after first- or -second-line LEN based treatment, HRQoL was maintained or trended toward improvement, despite the combination of 3 drugs with distinct toxicity profiles. In context with the previously reported safety and efficacy data from cohort B of MM-014, the results of this HRQoL analysis further support the earlier use of POM-based treatment in RRMM immediately following treatment with LEN.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Multiple myeloma, Quality of life

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies